HK Stock Market Move | LEADS BIOLABS-B (09887) rose over 4% in the afternoon. The core product LBL-024 is about to be launched, demonstrating the potential of a heavyweight single product.

LEADS BIOLABS-B (09887) rose more than 4% in the afternoon and as of the time of writing, it increased by 2.28% to 85.3 Hong Kong dollars, with a turnover of 37.3549 million Hong Kong dollars. On the news front, V1 Delcius Biosciences recently announced that the company's independently developed PD-L1/4-1BB bispecific antibody, Vilixin (LBL-024), has successfully completed the enrollment of the first patient in a Phase II clinical study for the frontline treatment of locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. GF SEC released a research report stating that the registration Phase IIb study of LBL-024 for 3L+EP-NEC has completed the enrollment of 96 patients in August 2025, with the BLA submission expected in Q3 2026; the product has expanded to 13 solid tumor indications in China and continues to show positive signals in 1LEP-NEC, 1LSCLC, and 1L/2+LNSCLC, with plans to update data at international conferences in 2026. Industrial also indicated that the imminent launch of LBL-024 demonstrates the potential of a blockbuster single product.